Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.

First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.

European urology. 2016 Jul 11 [Epub ahead of print]

Che-Kai Tsao, Matthew D Galsky, William K Oh

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: ., Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe